Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lack of Anavex doing much of what they say and have said they will do?
The UK just have a lot of unofficial tea breaks.
Well then I'm not sure why you started out objected to that concept. Perhaps just forced by the circumstance of your $AVXL investment. Better late than never.
I am amazed that some here haven't recognised that yet, but at least two now have.
I am arguing that your original apparent beef with my posts was that I said and maintain that to date we haven't seen any price sustainable events published by Anavex. Glad to see you now agree, but oh my it took you a long time to get to that simple understanding.
Mr. "fort night" is good at accusing others of lack of comprehension, while hiding behind a transparent curtain of ignorance and cluelessness.
So could still be a few years before perhaps something happens that will sustain $AVXL at higher prices?
The topline P2b/3 data was released Dec. 2022 and it was a fumble!
a chance our top line 2b/3 trial data will be released?
Maybe, definitely maybe!
There are no other forces than Anavex forces stopping Missling and crew from conducting successful clinical trials and then actually file an application to get A2-73 approved in something. All the conspiracy pendling is irrelevant to and not going to address the situation we are currently witness to.
And you have a reference to this claim?
and his still taking blarcamesine
I know but your point isn’t the one Kaufman is making.
Was that your point?
No that quote I took from the 2018 article, read that article again!
If you have also found the same quote from a 2021 article you have helped yourself understand what I told you.
You said:
Consider that if the Rett trial had not had such a strong response in the placebo group there would be an NDA filed by now
Walter E Kaufmann, MD, Chief Scientific Officer of Anavex commented, “We believe that a high placebo response may have masked the therapeutic effect of this innovative orally available molecule. High placebo responses are well documented especially in pediatric clinical studies. Although data analysis is ongoing, the early conclusion is that the placebo rate could have been higher in the study due to a slight imbalance in disease severity at baseline, across the treatment arms, and the 2 to 1 drug to placebo randomization ratio. We intend to further assess the collective results and discuss with the regulatory authorities next steps.”
Hint! Retrospective!
Five years ago, the acclaimed academic noticed he was becoming forgetful and was struggling with simple tasks like reading maps. Brain scans confirmed he was in the early stages of the degenerative condition.
Now, Dr Pittock is participating in a trial with Australian researchers and sees it as one of his final contributions to science.
"I want to be useful. I wanted to do something that had some practical value to humanity," he said.
I might consider a review if you make a start on apologising for all your nonsense and misleading predictions, your lack of understanding set theory and your endless pumping.
Did you retire from the federal conspiracy agency?
Its certainly not the first time you have been found to be wrong, Georgejjl!!!
https://clinicaltrials.gov/study/NCT04314934
Study Start (Actual) 2019-10-10
Georgejjl, the article link you posted is from 2018! There was no P2b/3 AD trial back then, duh!
Another blatant super pumper lie!!!
I said nothing significant! A3-71 results of P2 PK dose finding trial won't be significant in terms of $AVXL as an investment.
That's probably going to be the next time $AVXL takes another major nose dive.
Wait until you hear about the efficacy results from Avavex 3-71.
There is no fear of missing out on anything significant in over a year Georgejjl!!!
Whats up D-Mike, lost the $AVXL WGT mojo?
Another opportunity for Missling to tank $AVXL. Can't be bothered to listen to it.
Law firms will keep advertising for plaintiffs until close to the expiry of the lead plaintiff deadline - Its what they do! The reason being that the Private Securities Litigation Act (PSLRA) stipulates a lead plaintiff deadline to ensure that if, there is ultimately is a certified class it best represents all those damaged.
Great if no one else shows! Then we can pretty much close the book on this case too, especially so given the last court order, so just let it ride till 13th May.
Missling spoke and as expected is reflected in the $AVXL price. There was no tangible news of any progress, just more 'promises'...
Ok then you get second smartest post of the day for copying and pasting the link.
Folks could simply go to courtlistener.com and use the site to get even smarter.
Smartest post of the day!
Be smart and copy paste the link to some scratch pad so you can see it!
As I said RECAP is a plugin for the CourtListner site that recaps dockets downloaded from PACER to the site.
From the courtlistener.com RECAP archive, which you would know if you had looked at the URL. Same site as I have previously referenced.
RECAP means that someone with PACER access used their logon through Courtlistener and volunteered a copy of the docket to the site.
Yes interesting scribbles on the docket. Likely by the court/judge, since RECAP is plugin that directly copies the docket from pacer to courtlistener.
Good move by K&L Gates on behalf of Anavex: Re: Blum v. Anavex Life Sciences Corp., No. 1:24-cv-1910-CM
Essentially there won't be any case unless further parties join through motions for lead plaintiff within the 60 day deadline. Anavex can then wait for a potentially more coherent amended and consolidated complaint before having to respond, or never respond if no one else turns up and the case is dismissed.
As I previously mention if no one files a motion for lead plaintiff, its a good indication that the case has no merit.
Dear Judge McMahon: C}. 1) ~ We represent Defendants Anavex Life Sciences Corporation and Christopher Missling
("Defendants") in the above-captioned matter. We have conferred with counsel for Plaintiff and
write to requ est a stay of the deadline to respond to the currently operative complaint pending :P0/L ;~
resolution of the lead plaintiff process pursuant to the Private Securities Litigation Reform Act ~
("PSLRA"), 15 U.S.C. § 78u-4. Plai ntiff consents to this request.
We observe that section IV.M of Your Honor's Individual Practices and Procedures {}
provides that, in cases su bject to the PSLRA, the Court shall set a schedule for fil ing a J ~j/
consol idated amended complaint and briefing motions to dismiss after selection of a lead plaintiff C ~'
In the meantime, however, there are deadlines on the docket for Defendants to respond to the
currently operative complaint. Consistent with the apparent intent of the Court's Individual
Practices and to promote efficiency in light of the required lead plaintiff process, the parties o:/1
propose that deadlines to respond to the current complaint be stayed pending selection of a lead
plaintiff and the filing of a consolidated amended complaint (or notification that the lead plai~tiff )
wishes to proceed under the currently operative complaint) . :,-r ~
Thank you for your cons1derat1on . f' ("' .fl
Sincerely,
Theodore L. Kornobis
The longer we wait the sooner A2-73 will prophylactic.
Missling has just been reading this MB and picking up things that will please when mentioned. There is no real evidence that any FDA filing is eminent. As usual what he said have no deadlines. Even if it had we know how unlikely it would be that a catalyst expectation was met with any normal margin of error.
I no longer and haven't for while now believed anything Missling says about catalysts and Anavex trial success. Looking increasingly more like Madoff than TGD to me, but oh how nice it would be for once to be proven wrong about Anavex.
Unfortunately Anavex have not yet filed any regulatory approval applications!
unfortunately many of science's most important advances have faced market reluctance due to competing entities already accepted.
Results count!
many trials have been completed to date
When Missling speaks there is always action!
all talk and no action
Yeah Rett would save the day, but since it now won't AD is the new 85% chance WGT hope. But AD too may need another trial probably with A3-71 in years to come.